Glaucoma Burden Projections to 2050
Cross-source consensus on Glaucoma Burden Projections to 2050 from 1 sources and 5 claims.
1 sources · 5 claims
Benefits
Risks & contraindications
Comparisons
Evidence quality
Highlighted claims
- ARIMA projections were validated via Ljung-Box Q-testing for residual independence and a mean absolute percentage error below 10%. — Global, regional and national burden of glaucoma from 1990 to 2021 and projections to 2050: a retrospective cross-sectional study
- Projected growth in absolute glaucoma cases (+24.2%) and DALYs (+31.88%) by 2050 represents a marked slowdown relative to the 86.3% case increase observed over 1990–2021. — Global, regional and national burden of glaucoma from 1990 to 2021 and projections to 2050: a retrospective cross-sectional study
- Population ageing and increased longevity may cause actual future burden to exceed ARIMA projections. — Global, regional and national burden of glaucoma from 1990 to 2021 and projections to 2050: a retrospective cross-sectional study
- Low-SDI regions, particularly in Western Sub-Saharan Africa, are expected to continue bearing disproportionate burden through 2050 absent targeted intervention. — Global, regional and national burden of glaucoma from 1990 to 2021 and projections to 2050: a retrospective cross-sectional study
- Declining projected age-standardised rates suggest potential benefits from improved diagnostics, healthcare access, and socioeconomic development. — Global, regional and national burden of glaucoma from 1990 to 2021 and projections to 2050: a retrospective cross-sectional study